Global Blood Therapeutics Commitment to Sickle-Cell Innovation
In this rebroadcast episode, we flash back to a previous interview with Dr. Ted W. Love, President and CEO of Global Blood Therapeutics (GBT). Dr. Love spoke with our biotechnology analyst Gregory Renza about GBT’s mission-driven culture which led to the development of Oxbryta, the company’s breakthrough sickle-cell treatment, as well as the specific challenges the company faced in tackling a rare orphan disease. GBT was acquired by Pfizer in October 2022, reinforcing their commitment to sick cell disease and continuing to build on their 30-year legacy in the rare hematology space.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of Pathfinders in Biopharma?
This episode is 22 minutes long.
When was this Pathfinders in Biopharma episode published?
This episode was published on May 22, 2023.
Can I download this Pathfinders in Biopharma episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.